Non-small cell lung cancer-associated tumor antigen and T-cell surface glycoprotein CD3 (NSCLC TAA x CD3)

The target "Non-small cell lung cancer-associated tumor antigen and T-cell surface glycoprotein CD3" refers to a therapeutic strategy involving bispecific antibodies or T-cell engagers designed to treat non-small cell lung cancer (NSCLC). This approach utilizes one binding arm to target a specific, often proprietary or undisclosed, tumor-associated antigen (TAA) expressed on the surface of NSCLC cells, while the second arm binds to the CD3 epsilon subunit of the T-cell receptor complex on cytotoxic T-lymphocytes. By physically bridging the immune cell and the cancer cell, these agents induce the formation of an artificial immunological synapse, leading to potent T-cell activation and directed lysis of the tumor cell. This mechanism is independent of traditional major histocompatibility complex (MHC) class I recognition, allowing the immune system to target tumor cells that may have downregulated MHC expression. Common antigens explored in this context for NSCLC include DLL3, CEACAM5, and HER2, although the specific antigen in this case remains unidentified.

Other names

Undisclosed NSCLC antigen and CD3NSCLC-associated tumor antigen x CD3Tumor-associated antigen and CD3NSCLC TAA x CD3 bispecific

Bispecific T-cell engagement